Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
COGNITION THERAPEUTICS INC (CGTX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/24/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/04/2023 |
8-K
| Quarterly results |
05/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/03/2023 |
3
| Doyle John Brendan (CFO) has filed a Form 3 on COGNITION THERAPEUTICS INC |
05/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/19/2023 |
8-K
| Quarterly results |
03/28/2023 |
8-K
| Quarterly results |
03/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/23/2023 |
8-K
| Quarterly results |
03/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
03/10/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
03/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs:
|
"292 Arch Street Suit",
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Thirty-Five Million Dollars of the Company’ s common stock, $0.001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the " Purchase Shares ." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings:            &...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 10, 2023, is entered into by and between COGNITION THERAPEUTICS, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A.           Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Thirty-Five Million Dollars of the Company's common stock, par value $0.001 per share , pursua..." |
|
02/22/2023 |
8-K
| Quarterly results |
02/13/2023 |
8-K
| Quarterly results |
02/07/2023 |
4
| Caggiano Anthony (Chief Medical Officer) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Granted 94,406 shares
@ $0 Granted 94,406 options to buy
@ $2.12, valued at
$200.1k
|
|
02/07/2023 |
4
| Ricciardi Lisa (CEO & President) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Granted 213,973 shares
@ $0 Granted 213,973 options to buy
@ $2.12, valued at
$453.6k
|
|
12/05/2022 |
SC 13D/A
| BIOS Memory SPV I, LP reports a 23% stake in Cognition Therapeutics, Inc. |
11/29/2022 |
4
| RICHSTONE ELLEN B (Director) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Bought 10,000 shares
@ $2.655, valued at
$26.6k
|
|
11/29/2022 |
4
| Fletcher Aaron G.L. (10% Owner) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Bought 1,973 shares
@ $2.6497, valued at
$5.2k
Bought 12,220 shares
@ $2.6497, valued at
$32.4k
Bought 1,871 shares
@ $2.6497, valued at
$5k
|
|
11/29/2022 |
4
| Kreis Leslie W. (10% Owner) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Bought 1,973 shares
@ $2.6497, valued at
$5.2k
Bought 12,220 shares
@ $2.6497, valued at
$32.4k
Bought 1,871 shares
@ $2.6497, valued at
$5k
|
|
11/18/2022 |
SC 13G
| HIRSCHMAN ORIN reports a 7% stake in Cognition Therapeutics, Inc. |
11/17/2022 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Bought 8,722 shares
@ $1.4, valued at
$12.2k
Bought 54,009 shares
@ $1.4, valued at
$75.6k
Bought 8,269 shares
@ $1.4, valued at
$11.6k
|
|
11/17/2022 |
4
| Kreis Leslie W. (Director) has filed a Form 4 on COGNITION THERAPEUTICS INC
Txns:
| Bought 8,722 shares
@ $1.4, valued at
$12.2k
Bought 54,009 shares
@ $1.4, valued at
$75.6k
Bought 8,269 shares
@ $1.4, valued at
$11.6k
|
|
11/16/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|
|
|